Dermata Therapeutics (DRMA)
NASDAQ:DRMA
Want to see DRMA full AI Analyst Report?
DRMA Stock Chart & Stats
$2.14
-$0.06(-4.41%)
At close: 4:00 PM EST
$2.14
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$1.10 - $8.00
Previous CloseN/A
Volume28.34K
Average Volume (3M)249.42K
Market Cap
$4.75M
Enterprise Value-$6.06M
Total Cash (Recent Filing)$6.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 18, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.31
Shares Outstanding4,022,143
10 Day Avg. Volume611,626
30 Day Avg. Volume249,418
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.35
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.85
Forecast
1Y Price Target
$4.00Price Target Upside86.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$15.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt materially reduces financial leverage and default risk for a pre-revenue biotech. This durable strength preserves strategic optionality to fund R&D or partner deals without immediate interest obligations, improving flexibility across 2–6 months.
Improving Cash-flow TrendA narrowing of free cash flow losses indicates operational improvements or cost control that can extend runway. Sustained FCF improvement over multiple quarters reduces near-term financing pressure and raises the probability of reaching clinical inflection points before large new raises.
Enhanced Capital-raising And Governance FlexibilityApproval to expand equity incentives and permit warrant issuance/repricing strengthens the company’s ability to access equity capital and retain talent. Durable benefit: clearer governance and financing tools support execution of clinical programs and strategic partnerships.
Bears Say
Pre-revenue Business ModelNo product revenue means the company remains fully dependent on capital markets or partners to fund operations. Without demonstrated commercialization, commercial viability and sustainable margins remain uncertain for the foreseeable 2–6 month horizon.
Persistent Cash BurnMulti-year negative operating and free cash flow of roughly -$8.3M TTM creates structural funding dependency. Ongoing cash consumption pressures dilution risk, limits ability to run parallel trials, and forces management to prioritize near-term financing over long-term optionality.
Small Asset Base / Limited RunwayRelatively small total assets and modest equity imply limited internal resources to support extended clinical development. This constrains strategic choices (manufacturing scale, multiple programs) and increases urgency to secure external capital or partnerships to reach key milestones.
Dermata Therapeutics News
DRMA FAQ
What was Dermata Therapeutics’s price range in the past 12 months?
Dermata Therapeutics lowest stock price was $1.10 and its highest was $8.00 in the past 12 months.
What is Dermata Therapeutics’s market cap?
Dermata Therapeutics’s market cap is $4.75M.
When is Dermata Therapeutics’s upcoming earnings report date?
Dermata Therapeutics’s upcoming earnings report date is Aug 18, 2026 which is in 64 days.
How were Dermata Therapeutics’s earnings last quarter?
Dermata Therapeutics released its earnings results on May 13, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.53 by $0.05.
Is Dermata Therapeutics overvalued?
According to Wall Street analysts Dermata Therapeutics’s price is currently Undervalued.
Does Dermata Therapeutics pay dividends?
Dermata Therapeutics does not currently pay dividends.
What is Dermata Therapeutics’s EPS estimate?
Dermata Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Dermata Therapeutics have?
Dermata Therapeutics has 4,022,143 shares outstanding.
What happened to Dermata Therapeutics’s price movement after its last earnings report?
Dermata Therapeutics reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.53. Following the earnings report the stock price went up 3.361%.
Which hedge fund is a major shareholder of Dermata Therapeutics?
Currently, no hedge funds are holding shares in DRMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dermata Therapeutics
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
DRMA Stock 12 Month Forecast
Average Price Target
$4.00
▲(86.92% Upside)
Technical Analysis
―
Revelation Biosciences
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
31.57% Insiders
0.56% Mutual Funds
0.54% Other Institutional Investors
67.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---